PEGylated haemoglobin and carbon monoxide

Drug Profile

PEGylated haemoglobin and carbon monoxide

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; Sanguinate

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Haemoglobins; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Sickle cell anaemia
  • Phase I Hypoxia
  • Clinical Phase Unknown Beta-thalassaemia

Most Recent Events

  • 17 May 2017 Prolong Pharmaceuticals completes a phase-I trial in Anaemia in USA (IV) (NCT02754999)
  • 12 May 2017 Prolong Pharmaceuticals terminates a phase I pharmacokinetic trial according to the results published at the 2017 American Transplant Congress in USA (IV) (NCT02437422)
  • 02 May 2017 Prolong Pharmaceuticals plans a phase II trial for Ischemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top